Related Experiment Videos
[Glutamate transporter and neuronal cell death]
H Kawakami1, H Yamashita, T Nakayama
1Third Department of Internal Medicine, Hiroshima University.
Rinsho Shinkeigaku = Clinical Neurology
|December 1, 1996
Summary
Regulating glutamate transporters, like human glutamate transporter 1 (hGluT-1), can prevent neurotoxicity. Inhibiting glutamate efflux or enhancing uptake offers new strategies for treating neuronal damage in conditions like stroke and ALS.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Glutamate transporters are crucial for maintaining low extracellular glutamate levels, preventing neurotoxicity.
- Dysfunctional glutamate transport is implicated in ischemic conditions and neurodegenerative diseases like amyotrophic lateral sclerosis (ALS).
Purpose of the Study:
- To investigate the role of human glutamate transporter 1 (hGluT-1) in regulating extracellular glutamate.
- To identify potential therapeutic strategies for preventing excitotoxicity by modulating glutamate transporter activity.
Main Methods:
- Cloning of the human glutamate transporter hGluT-1.
- Utilizing HeLa cells expressing hGluT-1 to study glutamate transporter function.
- Assessing the effects of L-CCG-III, L-CCG-IV, glutamate, and bromocriptine on glutamate uptake and efflux.
Main Results:
- L-CCG-III, L-CCG-IV, and glutamate were shown to block reverse uptake (efflux) of glutamate in hGluT-1 expressing cells.
- Bromocriptine significantly enhanced glutamate uptake by 1.5 times in hGluT-1 expressing cells.
- Decreased glutamate transporter GLT1 is linked to elevated extracellular glutamate and neuronal injury in ALS.
Conclusions:
- Modulators of glutamate transporters present novel therapeutic avenues for preventing neuronal cell death.
- Targeting glutamate transporter activity, either by blocking efflux or enhancing uptake, may mitigate excitotoxicity in neurological disorders.